CCG-0954--GEMCITABINE IN CHILDREN WITH RELAPSED SOLID TUMORS

CCG-0954--吉西他滨治疗复发性实体瘤儿童

• 批准号: 6276878
• 负责人: JAMES A WHITLOCK
• 金额: $ 3.29万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276878
• 关键词: antineoplastics; child (0-11); clinical research; clinical trials; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; intravenous administration; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; pediatric pharmacology; pharmacokinetics

Determine the maximum tolerable dose and toxicities of gemcitabine given as a 30 minute intavenous infusion weekly for 3 weeks followed by a one week rest. Also, determine the pharmacokinetics in male and female pediatric patients and anti-tumor activity within the confines of a Phase I study. We continue to enroll patients which remains the focus of this multicenter study.

确定吉西他滨的最大耐受剂量和毒性 每周静脉输注30分钟，持续3周，然后是1次 周休息。此外，测定雄性和雌性动物的药代动力学 儿科患者和阶段范围内的抗肿瘤活性 我学习。 我们继续招募患者，这仍然是我们的重点。 多中心研究。